Skip to main content
    K

    Kairos Pharma, Ltd. (KAPA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • AMEX

    $0.41
    -0.04 (-8.82%)

    Market Cap: $1.54M

    Last updated: Nov 17, 2026 at 11:03 AM ET

    Kairos Pharma, Ltd. (KAPA) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Kairos Pharma are Calidi Biotherapeutics (CLDI), PharmaCyte Biotech (PMCB) and Scinai Immunotherapeutics (SCNI). By market cap, Kairos Pharma ranks 12th of the 13 companies on this page; Liminatus Pharma, Inc. Class A Common Stock (LIMN) is the largest at $4.02M.

    Peer Comparison

    KAPA's revenue growth of 0.0% is in line with the peer median. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Kairos Pharma (KAPA)$1.54MN/AN/A0.0%N/A0.0%0.00%
    Calidi Biotherapeutics Inc. (CLDI)$2.29MN/AN/A0.0%N/A0.0%0.00%
    PharmaCyte Biotech Inc (PMCB)$3.77MN/AN/A0.0%N/A0.0%0.00%
    Scinai Immunotherapeutics Ltd (SCNI)$1.05MN/AN/A-80.1%N/A572.0%0.00%
    Curis Inc (CRIS)$2.97MN/A1.6x0.0%N/A-66.0%0.00%
    Purple Biotech (PPBT)$2.65MN/AN/A0.0%-156.2%0.0%0.00%
    Enlivex Therapeutics Ltd (ENLV)$1.82MN/AN/A0.0%-0.3%0.0%0.00%
    Ernexa Therapeutics Inc. (ERNA)$2.84MN/AN/A0.0%N/A-94.1%0.00%
    XORTX Therapeutics Inc (XRTX)$2.00MN/AN/A0.0%N/A0.0%0.00%
    Genprex Inc (GNPX)$1.71MN/AN/A0.0%N/A0.0%0.00%
    Revelation Biosciences Inc (REVB)$2.43MN/AN/A0.0%N/A0.0%0.00%
    60 Degrees Pharmaceuticals, Inc. Common Stock (SXTP)$1.82MN/A1.7x0.0%N/A-32.5%0.00%
    Liminatus Pharma, Inc. Class A Common Stock (LIMN)$4.02MN/AN/A0.0%-247.2%0.0%0.00%
    Peer median$2.36MN/A1.7x0.0%-156.2%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Kairos Pharma, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Calidi Biotherapeutics Inc. (CLDI)
    Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing immunotherapies for the treatment of cancer.
    CLDI competitors
    PharmaCyte Biotech Inc (PMCB)
    PharmaCyte Biotech, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cell therapies for cancer and diabetes in the United...
    PMCB competitors
    Scinai Immunotherapeutics Ltd (SCNI)
    Scinai Immunotherapeutics Ltd is an innovative biotechnology company focused on developing cutting-edge immunotherapy solutions for cancer and autoimmune...
    SCNI competitors
    Curis Inc (CRIS)
    Curis, Inc., a biotechnology company, is dedicated to the discovery and development of drug candidates for the treatment of human cancers in the United States.
    CRIS competitors
    Purple Biotech (PPBT)
    Purple Biotech Ltd., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various pharmaceutical drugs in the United...
    PPBT competitors
    Enlivex Therapeutics Ltd (ENLV)
    Enlivex Therapeutics Ltd. is a clinical stage immunotherapy company. The company is headquartered in Nes Ziona, Israel.
    ENLV competitors
    Ernexa Therapeutics Inc. (ERNA)
    Brooklyn ImmunoTherapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to developing therapies to treat cancer patients.
    ERNA competitors
    XORTX Therapeutics Inc (XRTX)
    XORTX Therapeutics Inc., a biopharmaceutical company, is dedicated to the development and commercialization of therapies to treat progressive kidney disease...
    XRTX competitors
    Genprex Inc (GNPX)
    Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes.
    GNPX competitors
    Revelation Biosciences Inc (REVB)
    Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development of immunological diagnostics and therapeutics...
    REVB competitors
    60 Degrees Pharmaceuticals, Inc. Common Stock (SXTP)
    60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company that engages in the development and commercialization of therapies for the prevention...
    SXTP competitors
    Liminatus Pharma, Inc. Class A Common Stock (LIMN)
    Liminatus Pharma, Inc. is a clinical-stage immuno-oncology company that develops novel cancer therapies. The company is headquartered in LA Palma, California.
    LIMN competitors

    Frequently Asked Questions About KAPA

    Who are Kairos Pharma's main competitors?

    The companies most similar to Kairos Pharma include Calidi Biotherapeutics (CLDI), PharmaCyte Biotech (PMCB), Scinai Immunotherapeutics (SCNI), Curis (CRIS) and Purple Biotech (PPBT), listed from the closest match.

    Who is Kairos Pharma's biggest competitor?

    Liminatus Pharma, Inc. Class A Common Stock (LIMN) is the largest of the similar companies at $4.02M; Calidi Biotherapeutics (CLDI) is the closest match by business profile, size, sector and industry.

    How does KAPA stock compare with its competitors?

    KAPA's net margin is 0.0% against a peer median of 0.0%.

    Which of Kairos Pharma's competitors pays a higher dividend?

    Kairos Pharma pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Kairos Pharma bigger than its competitors?

    No. Kairos Pharma is 12th by market cap among the 13 companies on this page; the largest is Liminatus Pharma, Inc. Class A Common Stock (LIMN) at $4.02M.